MannKind Corporation
Afrezza
type 1 diabetes (pediatric)
Resolved
39days ago
FDA decision · ~ May 29, 2026 estimated
What's at stake
The FDA's approval decision on Afrezza for type 1 diabetes (pediatric) is due ~ May 29, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“In October 2025, the FDA accepted for review a supplemental BLA for Afrezza in children and adolescents between the ages of 4-17 who are living with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026.”